Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TriamHexal with or without bevacizumab for keloid lesions
IRCT20131119015455N5Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Oct 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in keloid comparing Intervention: TriamHexal + Avastin with Control: TriamHexal alone (2 arms). Primary endpoints: Improvement rate according to physician's point of view, Patient satisfaction score and 1 more. Started Oct 2019; status: completed.
02
Drugs
triamcinolone acetonidebevacizumab
03
Conditions
keloid
Beyond the preview
Go deeper on IRCT20131119015455N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20131119015455N5.